(2011) found that experimentally blocking IL‐1 receptors improved cognitive test performance in a triple transgenic (3 × Tg) mouse model of AD displaying both Aβ and tau neuropathology, suggesting that IL‐1 could be a major contributor to cognitive deficits seen in AD. Here, MAPT is linked to Alzheimer disease.